Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Monday, Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on LXRX. Leerink Partnrs reissued an outperform rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. SVB Leerink started coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They set an outperform rating and a $5.00 target price for the company. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Friday, May 3rd. Finally, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a research report on Thursday, June 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $6.67.

Lexicon Pharmaceuticals Stock Down 1.2 %

LXRX opened at $1.68 on Monday. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. The company has a fifty day moving average of $1.74 and a two-hundred day moving average of $1.91. The stock has a market capitalization of $413.68 million, a price-to-earnings ratio of -2.02 and a beta of 1.38.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). The firm had revenue of $1.13 million during the quarter, compared to analysts’ expectations of $1.17 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. On average, research analysts expect that Lexicon Pharmaceuticals will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BVF Inc. IL boosted its holdings in Lexicon Pharmaceuticals by 22.2% in the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after purchasing an additional 4,440,300 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Lexicon Pharmaceuticals by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after purchasing an additional 420,854 shares during the last quarter. Boulder Hill Capital Management LP acquired a new position in Lexicon Pharmaceuticals in the 1st quarter valued at about $615,000. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals in the 1st quarter valued at about $105,000. Finally, KWB Wealth acquired a new position in Lexicon Pharmaceuticals in the 4th quarter valued at about $62,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.